Abstract:Thrombotic diseases have been considered major causes of death around the world. Treatments with thrombolytic drugs, such as recombinant tissue-plasminogen activator, urokinase, and streptokinase, are reported to have a life-threatening bleeding tendency. On the contrary, lumbrokinase, identified from Lumbricus rubellus , is specific to fibrin and does not cause excessive bleeding. It possesses fibrinolytic activity and activation of plasminogen to dissolve fibrin. Hence, the purification of fibrinolytic protein monomer from earthworm and antithrombotic evaluation and investigation of mechanisms are needed. In this study, a novel fibrinolytic protein EPF3, with strong fibrinolytic activity, was purified from Pheretima vulgaris by ion exchange and size exclusion chromatography. SDS PAGE, bottom-up proteomics analysis, de novo sequencing, and circular dichroism (CD) analysis were carried out for identification and characterization of it. EPF3, with a molecular weight of 25136.24 Da, consisted of 241 amino acids and contained various forms of secondary structures, including α-helix (3.9%), β-sheet (42.8%), β-turn (21.2%), and random coil (32.1%). It was a trypsin-like serine protease and stable at pH 7.0 to 11.0 and below 40°C. EPF3 was confirmed to possess an antithrombotic effect by ex vivo clot lysis test and fibrinogen-thrombin time (Fib-TT) assay. The three-dimensional structure of EPF3 was predicted by SWISS-MODEL. Molecular docking analysis predicted that EPF3 could directly interact with antithrombotic target proteins (fibrin, fibrinogen, and plasminogen), which was further confirmed by further studies. The antithrombotic mechanism of EPF3 was clarified to be outstanding direct fibrinolysis, fibrinogenolytic activity, and certain activation of plasminogen. EPF3 possesses the potential to be developed into a promising antithrombotic agent.

Pharmaceutical methods of identifying fibrinolytic activity

Novel Distribution Pattern of Fibrinolytic Components in Rabbit Tissues Extract: a Preliminary Study

Role Of Fibrinolytic Enzymes In Anti-Thrombosis Therapy

A Novel Fibrinolytic Protein From Pheretima vulgaris: Purification, Identification, Antithrombotic Evaluation, and Mechanisms Investigation

Advances in Inhibitors of Fxa

A Bi-Functional Anti-Thrombosis Protein Containing Both Direct-Acting Fibrin(Ogen)Olytic And Plasminogen-Activating Activities

Progress in Study of Structure-Function Relationship and Protein Engineering of Plasminogen Activators

Development of a Methodology Based on Optical Interferometry for Measuring Fibrinolytic Activity

Food As Preventive Medicine

Microbial Fibrinolytic Enzymes: an Overview of Source, Production, Properties, and Thrombolytic Activity in Vivo

Contemporary medicinal-chemistry strategies for discovery of blood coagulation factor Xa inhibitors.

Hemorrhagic fibrino(geno)lytic enzymes from snake venom

[Effect of a Novel Fibrinolytic Enzyme FA-I on Thrombosis and Thrombolysis].

Development in the Research of Anticoagulant or Thrombolysis Peptide from Protein in Animal and Plant

Chemical Adjustment of Fibrinolysis

The Research Progress of Direct Thrombin Inhibitors

Comparative Analysis of Therapeutic Efficacy and Adverse Reactions among Various Thrombolytic Agents

Research Progress of Thrombolytic Enzymes

Anticoagulant protein:anticoagulant and thrombolysis mechanism

Discovery and development of Factor Xa inhibitors (2015-2022)

Therapeutic effects and molecular mechanisms of natural products in thrombosis